Cargando…
The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
There are many treatments for metastatic colorectal cancer (mCRC). Among them, uncertainty remains especially concerning the clinical benefit of different regimens for left-sided RAS wild-type (WT) mCRC in the triple-drug therapy era. No studies have been conducted to answer this critical clinical i...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561342/ https://www.ncbi.nlm.nih.gov/pubmed/36249804 http://dx.doi.org/10.3389/fphar.2022.1015510 |
_version_ | 1784807933067919360 |
---|---|
author | Cai, Changjing Luo, Qingqing Liu, Yihan Peng, Yinghui Zhang, Xiangyang Jiang, Zhaohui Feng, Ziyang Qi, Yaru Gao, Yan Liu, Yongting Liu, Ping Chen, Yihong Guo, Cao Shen, Hong Zeng, Shan Han, Ying |
author_facet | Cai, Changjing Luo, Qingqing Liu, Yihan Peng, Yinghui Zhang, Xiangyang Jiang, Zhaohui Feng, Ziyang Qi, Yaru Gao, Yan Liu, Yongting Liu, Ping Chen, Yihong Guo, Cao Shen, Hong Zeng, Shan Han, Ying |
author_sort | Cai, Changjing |
collection | PubMed |
description | There are many treatments for metastatic colorectal cancer (mCRC). Among them, uncertainty remains especially concerning the clinical benefit of different regimens for left-sided RAS wild-type (WT) mCRC in the triple-drug therapy era. No studies have been conducted to answer this critical clinical issue. We performed a comprehensive analysis of published data and real-world data. First, we conducted analyses of the published trials to show the landscape of efficacy and safety in the treatments of left-sided RAS WT mCRC. Then, we initiated a multicenter real-world study as the validation dataset. This study included six published randomized controlled trials (RCTs) and a total of 1925 patients. The double-drug regimen plus cetuximab/panitumumab (D + C/P) achieved the longest overall survival (OS) in patients with left-sided mCRC (HR = 0.74, 95%CI: 0.57–0.98), while triple-drug regimen with bevacizumab (T + B, HR = 1.1, 95%CI: 0.63–2.0), compared with double-drug with bevacizumab (D + B). The D + C/P had the highest overall response rate (ORR) in patients with left-sided mCRC (OR = 1.8, 95%CI: 0.89–3.8), while T + B (OR = 1.8, 95%CI: 0.70–4.8), compared with D + B. The multicenter real-world cohort showed the double-drug regimen plus cetuximab had longer progression-free survival (PFS) in left-sided mCRC patients than the triple-drug regimen with bevacizumab. The safety analysis showed the incidence of the adverse events (grade≥3) in the triple-drug therapy plus bevacizumab was higher than that in the double-drug therapy plus cetuximab/panitumumab. This work demonstrates the ranking of three regimens for therapeutic efficacy and safety in patients with left-sided RAS WT mCRC. The double-drug regimen plus cetuximab/panitumumab appears more effective and safer than double-drug and triple-drug based regimens with bevacizumab. Further trials and cohort analyses on this topic would increase confidence in these results. |
format | Online Article Text |
id | pubmed-9561342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95613422022-10-15 The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy Cai, Changjing Luo, Qingqing Liu, Yihan Peng, Yinghui Zhang, Xiangyang Jiang, Zhaohui Feng, Ziyang Qi, Yaru Gao, Yan Liu, Yongting Liu, Ping Chen, Yihong Guo, Cao Shen, Hong Zeng, Shan Han, Ying Front Pharmacol Pharmacology There are many treatments for metastatic colorectal cancer (mCRC). Among them, uncertainty remains especially concerning the clinical benefit of different regimens for left-sided RAS wild-type (WT) mCRC in the triple-drug therapy era. No studies have been conducted to answer this critical clinical issue. We performed a comprehensive analysis of published data and real-world data. First, we conducted analyses of the published trials to show the landscape of efficacy and safety in the treatments of left-sided RAS WT mCRC. Then, we initiated a multicenter real-world study as the validation dataset. This study included six published randomized controlled trials (RCTs) and a total of 1925 patients. The double-drug regimen plus cetuximab/panitumumab (D + C/P) achieved the longest overall survival (OS) in patients with left-sided mCRC (HR = 0.74, 95%CI: 0.57–0.98), while triple-drug regimen with bevacizumab (T + B, HR = 1.1, 95%CI: 0.63–2.0), compared with double-drug with bevacizumab (D + B). The D + C/P had the highest overall response rate (ORR) in patients with left-sided mCRC (OR = 1.8, 95%CI: 0.89–3.8), while T + B (OR = 1.8, 95%CI: 0.70–4.8), compared with D + B. The multicenter real-world cohort showed the double-drug regimen plus cetuximab had longer progression-free survival (PFS) in left-sided mCRC patients than the triple-drug regimen with bevacizumab. The safety analysis showed the incidence of the adverse events (grade≥3) in the triple-drug therapy plus bevacizumab was higher than that in the double-drug therapy plus cetuximab/panitumumab. This work demonstrates the ranking of three regimens for therapeutic efficacy and safety in patients with left-sided RAS WT mCRC. The double-drug regimen plus cetuximab/panitumumab appears more effective and safer than double-drug and triple-drug based regimens with bevacizumab. Further trials and cohort analyses on this topic would increase confidence in these results. Frontiers Media S.A. 2022-09-30 /pmc/articles/PMC9561342/ /pubmed/36249804 http://dx.doi.org/10.3389/fphar.2022.1015510 Text en Copyright © 2022 Cai, Luo, Liu, Peng, Zhang, Jiang, Feng, Qi, Gao, Liu, Liu, Chen, Guo, Shen, Zeng and Han. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cai, Changjing Luo, Qingqing Liu, Yihan Peng, Yinghui Zhang, Xiangyang Jiang, Zhaohui Feng, Ziyang Qi, Yaru Gao, Yan Liu, Yongting Liu, Ping Chen, Yihong Guo, Cao Shen, Hong Zeng, Shan Han, Ying The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy |
title | The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy |
title_full | The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy |
title_fullStr | The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy |
title_full_unstemmed | The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy |
title_short | The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy |
title_sort | optimal first-line treatment for patients with left-sided ras wild-type metastatic colorectal cancer: double-drug regimen or triple-drug regimen therapy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561342/ https://www.ncbi.nlm.nih.gov/pubmed/36249804 http://dx.doi.org/10.3389/fphar.2022.1015510 |
work_keys_str_mv | AT caichangjing theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT luoqingqing theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT liuyihan theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT pengyinghui theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT zhangxiangyang theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT jiangzhaohui theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT fengziyang theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT qiyaru theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT gaoyan theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT liuyongting theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT liuping theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT chenyihong theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT guocao theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT shenhong theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT zengshan theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT hanying theoptimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT caichangjing optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT luoqingqing optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT liuyihan optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT pengyinghui optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT zhangxiangyang optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT jiangzhaohui optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT fengziyang optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT qiyaru optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT gaoyan optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT liuyongting optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT liuping optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT chenyihong optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT guocao optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT shenhong optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT zengshan optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy AT hanying optimalfirstlinetreatmentforpatientswithleftsidedraswildtypemetastaticcolorectalcancerdoubledrugregimenortripledrugregimentherapy |